2021 brought a flurry of #MnA activity in the life sciences sector, followed by a slowdown in 2022. Here’s why dealmaking could pick up again. deloi.tt/3PIOHZP
– Deloitte M&A (@DeloitteMnA)09:00 – Aug 31, 2022
Related Posts
Starboard Challenges Pfizer: Demands Accountability in M&A and R&D
Activist Investor Scrutiny: Starboard Value, a prominent activist investor, is calling for greater accountability from Pfizer's leadership over perceived overpaid M&A deals and poor returns on R&D...
Eye Care Giant Bausch + Lomb: $10B Debt Financing Bid Heats Up
Competitive Bidding Frenzy: Banks and private credit firms are engaged in an intense bidding war to secure a $5 billion debt financing deal for Bausch + Lomb, a prominent player in the eye care...
Cigna & Humana Revive Merger Talks Amid Medicare Cost Pressure
Strategic Rationale: The potential Cigna-Humana merger aims to achieve significant cost savings through economies of scale, enhancing their competitive position and offering more comprehensive...
France Secures Stake in Sanofi Unit, Safeguarding Jobs and Sovereignty
Strategic Intervention: France acquires stake in Sanofi's Opella unit to safeguard jobs and national interests amid potential $16B sale to US firm CD&R. Pharmaceutical Landscape: Sanofi, a...